In contrast, Dasatinib, a drug that is used for treating chronic myelogenous leukemia and has a half maximal inhibitory concentration (IC50) of 8.5 nM against Lyn [63], completely inhibited Lyn kinase activity at the concentration of 10 μM. Here, LYN is linked to chronic myelogenous leukemia, BCR-ABL1 positive.